MyBlueDotsBioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution MyBlueDots4 weeks ago01 mins DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells. Post navigation Previous: Instem Introduces Cloud-Hosted Non-GLP Pathology Module for ProvantisNext: RefleXion Launches Pivotal Study to Expand SCINTIX Therapy and Announces Broader Medicare Reimbursement
Generally, things really do seem better in the morning, large study suggests MyBlueDots18 hours ago 0
GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds MyBlueDots18 hours ago 0
Review finds women health sector leaders good for a nation’s wealth, health, innovation, ethics MyBlueDots18 hours ago 0